Interesting developments on the Science front – courtesy of Facebook pages, ‘Dr Erikson’, ‘Daily Insider’, ‘Today I Learned’, ‘Science and Facts’, etc… Although trials, experiments and studies show promise, I guess it will be some time yet before they are a reality.
A pioneering clinical trial has shown that adult stem cell transplants can safely restore vision in people with advanced dry age‑related macular degeneration (AMD). Researchers used retinal pigment epithelial stem cells derived from adult postmortem eye tissue and transplanted them into the eyes of participants. In the initial low‑dose group, patients experienced measurable improvements in the treated eye, gaining the ability to read additional letters on standard vision tests, while the untreated eye showed no change.
The study focused on dry AMD, which occurs when retinal pigment epithelial cells malfunction and die, leading to progressive loss of central vision. Transplanted stem cells were limited to maturing into these critical retinal cells, helping replenish damaged tissue in the macula. Safety was confirmed, with no serious inflammation or tumor formation reported. The early success demonstrates that even in severely affected patients, replacing lost retinal cells can improve visual function.
Researchers are now monitoring participants who received higher doses and plan to expand the trial into later stages if no safety concerns arise. This work highlights the potential of regenerative medicine to not only slow degeneration but also restore sight in conditions where existing therapies only prevent further decline. – A Facebook post
A study published in Oncotarget examined the effect of an aqueous dandelion root extract on colon cancer cells. Researchers found that the extract triggered programmed cell death in more than 95 percent of colon cancer cells within 48 hours, and notably did so regardless of the cancer cells' p53 status, a gene often involved in cancer resistance. Just as importantly, the extract did not harm normal, non-cancerous colon cells exposed to the same doses, suggesting it acted selectively. By comparison, a standard chemotherapy combination tested alongside it affected both cancerous and healthy cells.
The researchers also tested the extract in mouse models carrying human colon cancer tissue. Oral administration of the extract slowed tumor growth by more than 90 percent in these models. Analysis suggested the extract worked by activating several different cell death pathways at once, which the researchers attributed to its complex mixture of natural compounds including alpha-amyrin, beta-amyrin, lupeol, and taraxasterol. Interestingly, the individual compounds were less effective on their own than the whole extract, pointing to a combined effect.
It is essential to be clear about what this research does and does not show. These results come from cancer cells studied in the laboratory and from mice, not from human patients. Dandelion root extract has not been shown to treat or cure cancer in people, and it is not a substitute for conventional cancer treatment. Anyone facing a cancer diagnosis should always work with their medical team, as delaying proven treatment can be dangerous.
What the study does offer is a promising direction for future research. The hope among the researchers is that natural compounds like these could one day be developed into non-toxic options that complement existing therapies, but confirming that will require much more study, including clinical trials in humans. - A Facebook post by Dr Erikson
Scientists have created what they call a "ghost heart" — and it may be the most important medical breakthrough of our lifetime.
Here is how it works. They take a pig heart, wash it gently with a mild detergent until every single cell dissolves away. The blood drains out. The color fades. What is left behind is a ghostly white protein scaffold — the architectural skeleton of a heart, perfectly intact, right down to the tiniest blood vessel channels.
Then they inject it with the patient's own stem cells.
The cells find their way into the scaffold, settle in, and begin to grow. Scientists have already watched these hybrid hearts start beating in the lab.
The reason this changes everything is rejection. Every year, thousands of transplant patients die not because they did not get an organ — but because their body attacked it. With a ghost heart rebuilt from your own stem cells, there is nothing foreign for your immune system to fight. No rejection. No lifelong anti-rejection drugs.
Right now, over 103,000 Americans are on the transplant waiting list. 13 people die every day waiting for an organ that never comes. One in three heart patients dies before a donor heart even becomes available.
And here is the part that should be on the front page of every newspaper. In June 2025, this technology was used on a real human patient for the first time — not the heart yet, but a bioengineered liver built using the exact same method. It worked. The organ performed all the functions of a healthy liver in a patient who had no other options.
The heart is next. Researchers say a fully transplantable ghost heart could be ready within the next 6 to 7 years. We may be the last generation that dies waiting for a donor organ. – A Facebook post
The effort to utilize induced pluripotent stem cells (iPSCs) to treat Parkinson's disease has advanced from experimental research into a historic clinical reality.
In March 2026, Japan’s Ministry of Health, Labour and Welfare made history by granting the world's first conditional marketing approval for an iPSC-derived treatment for Parkinson's disease, brand-named Amchepry.
Developed by Sumitomo Pharma in collaboration with Dr. Jun Takahashi at Kyoto University, this milestone represents a monumental shift from chemically managing symptoms to actively rebuilding the brain's cellular infrastructure.
The standard treatment pathway relies on the landmark physician-led clinical trial framework conducted at Kyoto University Hospital.
This therapeutic strategy utilizes high-grade iPS cells sourced from healthy donors, which are meticulously reprogrammed and guided to mature into specialized dopamine-producing neural progenitor cells.
Using highly precise neurosurgical stereotactic navigation, surgeons implant between 5 million and 10 million of these lab-grown cells directly into the bilateral putamen—the central region of the brain where natural dopamine neurons have been destroyed by the disease.
Data from the two-year clinical monitoring period confirmed the profound efficacy and baseline safety of this regenerative approach. Out of the patients evaluated, the majority experienced significant, measurable motor function improvements on standard clinical scales while off their traditional medications.
High-resolution PET imaging confirmed that the transplanted cells not only successfully survived without abnormal cell proliferation or tumor formation, but aggressively increased dopamine synthesis by up to 63.5% in high-dose recipients.
Under Japan's specialized conditional approval pathway, the medicine is now available to eligible patients while researchers continue to monitor long-term safety and tracking data over the next seven years, offering a transformative blueprint for the future of regenerative medicine. – A Facebook post by ‘Daily Insider’
Researchers in South Korea have achieved a massive breakthrough in eye health by 3D-printing artificial corneas.
Using a unique "bioink" made from natural eye tissue and stem cells, they can replicate the delicate, complex layers of a human eye.
A key part of their success was using a technique called "shear stress" during the printing process. This ensures that tiny fibers line up perfectly, matching the structure of a real cornea. Older artificial eyes were often made of plastic, which the body frequently rejected. Because this new version uses natural materials, it is clear, flexible, and much safer for patients.
This discovery is a game-changer for millions of people suffering from vision loss.
Right now, there is a severe shortage of human eye donors, leaving many on long waiting lists. By growing these parts in a lab, doctors can provide life-changing transplants to anyone in need without waiting for a donor.
This blend of technology and medicine offers a bright future for those seeking to regain their sight. It is a powerful example of how science can solve ancient problems with modern tools. One day soon, everyone may see more clearly. – A Facebook post by ‘Daily Insider’
Thank you for stopping by. Follow me if you find my posts interesting. If you know of anyone who might appreciate them, do recommended the blog to them. Cheers!



































